Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HER2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 282 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Hosch, SB; Braun, S; Pantel, K
      Characterization of disseminated tumor cells

      SEMINARS IN SURGICAL ONCOLOGY
    2. Wolff, RA
      Novel therapies for pancreatic cancer

      CANCER JOURNAL
    3. Di Modugno, F; Buglioni, S; Mottolese, M; Del Bello, D; Cascioli, S; Chersi, A; Santoni, A; Nistico, P
      Polyclonal antibodies against gp185(HER2) peptides: Their putative role inthe identification of a particular HER2 status in patients with breast cancer

      JOURNAL OF IMMUNOTHERAPY
    4. Vaziri, SAJ; Tubbs, RR; Darlington, G; Casey, G
      Absence of CCND 1 gene amplification in breast tumours of BRCA1 mutation carriers

      JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY
    5. Dowsett, M
      Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

      ENDOCRINE-RELATED CANCER
    6. Tsuda, H; Tani, Y; Hasegawa, T; Fukutomi, T
      Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detectedby two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma

      PATHOLOGY INTERNATIONAL
    7. Hatanaka, Y; Hashizume, K; Kamihara, Y; Itoh, H; Tsuda, H; Osamura, RY; Tani, Y
      Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest(TM) in breast carcinoma by image analysis

      PATHOLOGY INTERNATIONAL
    8. Bendas, G
      Immunoliposomes - A promising approach to targeting cancer therapy

      BIODRUGS
    9. Normanno, N; Bianco, C; De Luca, A; Salomon, DS
      The role of EGF-related peptides in tumor growth

      FRONTIERS IN BIOSCIENCE
    10. Buchler, P; Reber, HA; Buchler, MC; Roth, MA; Buchler, MW; Friess, H; Isacoff, WH; Hines, OJ
      Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

      JOURNAL OF GASTROINTESTINAL SURGERY
    11. Schneeweiss, A; Goerner, R; Hensel, M; Lauschner, I; Sinn, P; Kaul, S; Egerer, G; Beldermann, F; Geberth, M; Solomayer, E; Grischke, EM; Haas, R; Ho, AD; Bastert, G
      Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    12. Troyer, KL; Lee, DC
      Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network

      JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
    13. Shepherd, T; Hassell, JA
      Role of Ets transcription factors in mammary gland development and oncogenesis

      JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
    14. Baselga, J
      Is circulating HER-2 more than just a tumor marker?

      CLINICAL CANCER RESEARCH
    15. Chiosis, G; Timaul, MN; Lucas, B; Munster, PN; Zheng, FF; Sepp-Lorenzino, L; Rosen, N
      A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells

      CHEMISTRY & BIOLOGY
    16. Kaptain, S; Tan, LK; Chen, BY
      Her-2/neu and breast cancer

      DIAGNOSTIC MOLECULAR PATHOLOGY
    17. Skirnisdottir, I; Sorbe, B; Seidal, T
      The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    18. Gilbertson, R; Hernan, R; Pietsch, T; Pinto, L; Scotting, P; Allibone, R; Ellison, D; Perry, R; Pearson, A; Lunec, J
      Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma

      GENES CHROMOSOMES & CANCER
    19. Tsongalis, GJ; Ricci, A
      HER2: The Neu prognostic marker for breast cancer

      CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
    20. Arencibia, JM; Schally, AV; Krupa, M; Bajo, AM; Nagy, A; Szepeshazi, K; Plonowski, A
      Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness

      INTERNATIONAL JOURNAL OF ONCOLOGY
    21. Krahn, G; Leiter, U; Kaskel, P; Udart, M; Utikal, J; Bezold, G; Peter, RU
      Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer

      EUROPEAN JOURNAL OF CANCER
    22. Thybusch-Bernhardt, A; Aigner, A; Beckmann, S; Czubayko, F; Juhl, H
      Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo

      EUROPEAN JOURNAL OF CANCER
    23. Piccart, M; Kaufmann, M
      Herceptin: HER2 status - Changing clinical practice - Introduction

      EUROPEAN JOURNAL OF CANCER
    24. Cooke, T; Reeves, J; Lannigan, A; Stanton, P
      The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

      EUROPEAN JOURNAL OF CANCER
    25. van de Vijver, MJ
      Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)

      EUROPEAN JOURNAL OF CANCER
    26. Baselga, J
      Clinical trials of Herceptin (R) (trastuzumab)

      EUROPEAN JOURNAL OF CANCER
    27. Vogel, C; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report

      EUROPEAN JOURNAL OF CANCER
    28. Piccart, M
      Closing remarks and treatment guidelines

      EUROPEAN JOURNAL OF CANCER
    29. Le, XF; Marcelli, M; McWatters, A; Nan, BC; Mills, GB; O'Brian, CA; Bast, RC
      Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity

      ONCOGENE
    30. Bosc, DG; Goueli, BS; Janknecht, R
      HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1

      ONCOGENE
    31. Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM
      Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor

      ONCOGENE
    32. Yang, HY; Shao, RP; Hung, MC; Lee, MH
      p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis

      ONCOGENE
    33. Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F
      Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation

      ONCOGENE
    34. Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ
      Src family kinases and HER2 interactions in human breast cancer cell growth and survival

      ONCOGENE
    35. Fountzilas, G; Tsavdaridis, D; Kalogera-Fountzila, A; Christodoulou, C; Timotheadou, E; Kalofonos, C; Kosmidis, P; Adamou, A; Papakostas, P; Gogas, H; Stathopoulos, G; Razis, E; Bafaloukos, D; Skarlos, D
      Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase IIstudy

      ANNALS OF ONCOLOGY
    36. Rubin, I; Yarden, Y
      The basic biology of HER2

      ANNALS OF ONCOLOGY
    37. Neve, RM; Lane, HA; Hynes, NE
      The role of overexpressed HER2 in transformation

      ANNALS OF ONCOLOGY
    38. Menard, S; Casalini, P; Campiglio, M; Pupa, S; Agresti, R; Tagliabue, E
      HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

      ANNALS OF ONCOLOGY
    39. Lane, HA; Motoyama, AB; Beuvink, I; Hynes, NE
      Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

      ANNALS OF ONCOLOGY
    40. Cooke, T; Reeves, J; Lanigan, A; Stanton, P
      HER2 as a prognostic and predictive marker for breast cancer

      ANNALS OF ONCOLOGY
    41. Valagussa, P
      HER2 status: A statistician's view

      ANNALS OF ONCOLOGY
    42. Baselga, J; Albanell, J
      Mechanism of action of anti-HER2 monoclonal antibodies

      ANNALS OF ONCOLOGY
    43. Leyland-Jones, B; Arnold, A; Gelmon, K; Verma, S; Ayoub, JP; Seidman, A; Dias, R; Howell, J; Rakhit, A
      Pharmacologic insights into the future of trastuzumab

      ANNALS OF ONCOLOGY
    44. Baselga, J
      Phase I and II clinical trials of trastuzumab

      ANNALS OF ONCOLOGY
    45. Eiermann, W
      Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

      ANNALS OF ONCOLOGY
    46. Gianni, L
      Tolerability in patients receiving trastuzumab with or without chemotherapy

      ANNALS OF ONCOLOGY
    47. Smith, I
      Future directions in the adjuvant treatment of breast cancer: The role of trastuzumab

      ANNALS OF ONCOLOGY
    48. Scholl, S; Beuzeboc, P; Pouillart, P
      Targeting HER2 in other tumor types

      ANNALS OF ONCOLOGY
    49. Piccart, MJ
      Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

      ANNALS OF ONCOLOGY
    50. Mrsic, M; Grgic, M; Budisic, Z; Podolski, P; Bogdanic, V; Labar, B; Jakic-Razumovic, J; Restek-Samarzija, N; Gosev, M
      Trastuzumab in the treatment of advanced breast cancer: Single-center experience

      ANNALS OF ONCOLOGY
    51. Schaller, G; Evers, K; Papadopoulos, S; Ebert, A; Buhler, H
      Current use of HER2 tests

      ANNALS OF ONCOLOGY
    52. Thor, A
      HER2 - a discussion of testing approaches in the USA

      ANNALS OF ONCOLOGY
    53. Schnitt, SJ
      Breast cancer in the 21st century: Neu opportunities and neu challenges

      MODERN PATHOLOGY
    54. Dillman, RO
      Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments

      CANCER INVESTIGATION
    55. Colomer, R; Shamon, LA; Tsai, MS; Lupu, R
      Herceptin: From the bench to the clinic

      CANCER INVESTIGATION
    56. Yamauchi, H; Stearns, V; Hayes, DF
      When is a tumor marker ready for prime time? A case study of c-erbB-2 as apredictive factor in breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    57. Bast, RC; Ravdin, P; Hayes, DF; Bates, S; Fritsche, H; Jessup, JM; Kemeny, N; Locker, GY; Mennel, RG; Somerfield, MR
      2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology

      JOURNAL OF CLINICAL ONCOLOGY
    58. Zhu, LL; Hou, TJ; Chen, LR; Xu, XJ
      Pharmacophore model analysis of novel tyrphostins

      ACTA CHIMICA SINICA
    59. Saijo, N; Tamura, T; Yamamoto, N; Nishio, K
      New strategies for cancer therapy in the 21st century

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    60. Penichet, ML; Dela Cruz, JS; Challita-Eid, PM; Rosenblatt, JD; Morrison, SL
      A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    61. Frolik, D; Caduff, R; Varga, Z
      Pleomorphic lobular carcinoma of the breast: its cell kinetics, expressionof oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas

      HISTOPATHOLOGY
    62. Koeppen, HKW; Wright, BD; Burt, AD; Quirke, P; McNicol, AM; Dybdal, NO; Sliwkowski, MX; Hillan, KJ
      Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

      HISTOPATHOLOGY
    63. Keshava, C; McCanlies, EC; Keshava, N; Wolff, MS; Weston, A
      Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States

      CANCER LETTERS
    64. Mokbel, K; Hassanally, D
      From HER2 to herceptin

      CURRENT MEDICAL RESEARCH AND OPINION
    65. Merati, K; Siadaty, MS; Andea, A; Sarkar, F; Ben-Josef, E; Mohammad, R; Philip, P; Shields, AF; Vaitkevicius, V; Grignon, DJ; Adsay, NV
      Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    66. Safran, H; Steinhoff, M; Mangray, S; Rathore, R; King, TC; Chai, L; Berzein, K; Moore, T; Iannitti, D; Reiss, P; Pasquariello, T; Akerman, P; Quirk, D; Mass, R; Goldstein, L; Tantravahi, U
      Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    67. Yaziji, H; Gown, AM
      Immunohistochemical analysis of gynecologic tumors

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
    68. Wang, L; Liu, BL; Schmidt, M; Lu, Y; Wels, W; Fan, Z
      Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells

      PROSTATE
    69. Foy, TM; Bannink, J; Sutherland, RA; McNeill, PD; Moulton, GG; Smith, J; Cheever, MA; Grabstein, K
      Vaccination with Her-2/neu DNA or protein subunits protects against growthof a Her-2/neu-expressing murine tumor

      VACCINE
    70. Meden, H; Beneke, A; Hesse, T; Novophashenny, I; Wischnewsky, M
      Weekly intravenous recombinant humanized anti-P185(HER2) monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study

      ANTICANCER RESEARCH
    71. Park, JW; Kirpotin, DB; Hong, K; Shalaby, R; Shao, Y; Nielsen, UB; Marks, JD; Papahadjopoulos, D; Benz, CC
      Tumor targeting using anti-her2 immunoliposomes

      JOURNAL OF CONTROLLED RELEASE
    72. Xu, L; Pirollo, KF; Chang, EH
      Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy

      JOURNAL OF CONTROLLED RELEASE
    73. Mueller-Holzner, E; Fink, V; Frede, T; Marth, C
      Immunohistochemical determination of HER2 expression in breast cancer fromcore biopsy specimens: a reliable predictor of HEr2 status of the whole tumor

      BREAST CANCER RESEARCH AND TREATMENT
    74. Kollara, A; Kahn, HJ; Marks, A; Brown, TJ
      Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers

      BREAST CANCER RESEARCH AND TREATMENT
    75. Su, WC; Shiesh, SC; Liu, HS; Chen, CY; Chow, NH; Lin, XZ
      Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders

      DIGESTIVE DISEASES AND SCIENCES
    76. Baselga, J; Albanell, J; Molina, MA; Arribas, J
      Mechanism of action of trastuzumab and scientific update

      SEMINARS IN ONCOLOGY
    77. Yu, DH
      Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

      SEMINARS IN ONCOLOGY
    78. Hortobagyi, GN; Perez, EA
      Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials

      SEMINARS IN ONCOLOGY
    79. Burstein, HJ; Bunnell, CA; Winer, EP
      New cytotoxic agents and schedules for advanced breast cancer

      SEMINARS IN ONCOLOGY
    80. Funkhouser, WK; Kaiser-Rogers, K
      Review: Significance of, and optimal screening for, HER-2 gene amplification and protein overexpression in breast carcinoma

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    81. Drummond, DC; Hong, KL; Park, JW; Benz, CC; Kirpotin, DB
      Liposome targeting to tumors using vitamin and growth factor receptors

      VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 60
    82. Park, JW; Smolen, J
      Monoclonal antibody therapy

      ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    83. Yarden, Y
      Biology of HER2 and its importance in breast cancer

      ONCOLOGY
    84. Baselga, J
      Herceptin((R)) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials

      ONCOLOGY
    85. Hanna, W
      Testing for HER2 status

      ONCOLOGY
    86. Vogel, CL; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line Herceptin (R) monotherapy in metastatic breast cancer

      ONCOLOGY
    87. Dieras, V; Beuzeboc, P; Laurence, V; Pierga, JY; Pouillart, P
      Interaction between Herceptin((R)) and taxanes

      ONCOLOGY
    88. Winer, EP; Burstein, HJ
      New combinations with Herceptin((R)) in metastatic breast cancer

      ONCOLOGY
    89. Menard, S; Fortis, S; Castiglioni, F; Agresti, R; Balsari, A
      HER2 as a prognostic factor in breast cancer

      ONCOLOGY
    90. Piccart, M; Lohrisch, C; Di Leo, A; Larsimont, D
      The predictive value of HER2 in breast cancer

      ONCOLOGY
    91. Leyland-Jones, B; Smith, I
      Role of Herceptin (R) in primary breast cancer: Views from North America and Europe

      ONCOLOGY
    92. Novotny, J; Petruzelka, L; Vedralova, J; Kleibl, Z; Matous, B; Judas, L
      Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients

      NEOPLASMA
    93. Matsuo, K; Fukutomi, T; Tsuda, H; Akashi-Tanaka, S; Shimizu, C; Hasegawa, T
      Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma

      JOURNAL OF SURGICAL ONCOLOGY
    94. Urbanelli, L; Ronchini, C; Fontana, L; Menard, S; Orlandi, R; Monaci, P
      Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage

      JOURNAL OF MOLECULAR BIOLOGY
    95. Piechocki, MP; Pilon, SA; Wei, WZ
      Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2

      JOURNAL OF IMMUNOLOGY
    96. Powers, DB; Amersdorfer, P; Poul, MA; Nielsen, UB; Shalaby, MR; Adams, GP; Weiner, LM; Marks, JD
      Expression of single-chain Fv-Fc fusions in Pichia pastoris

      JOURNAL OF IMMUNOLOGICAL METHODS
    97. Uno, M; Otsuki, T; Kurebayashi, J; Sakaguchi, H; Isozaki, Y; Ueki, A; Yata, K; Fujii, T; Hiratsuka, J; Akisada, T; Harada, T; Imajo, Y
      Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma

      INTERNATIONAL JOURNAL OF CANCER
    98. Cox, G; Vyberg, M; Melgaard, B; Askaa, J; Oster, A; O'Byrne, KJ
      HercepTest: HER2 expression and gene amplification in non-small cell lung cancer

      INTERNATIONAL JOURNAL OF CANCER
    99. Baral, R; Sherrat, A; Das, R; Foon, KA; Bhattacharya-Chatterjee, M
      Murine monoclonal anti-idiotypic antibody as a surrogate antigen for humanHer-2/neu

      INTERNATIONAL JOURNAL OF CANCER
    100. Carter, WB; Hoying, JB; Boswell, C; Williams, SK
      HER2/neu over-expression induces endothelial cell retraction

      INTERNATIONAL JOURNAL OF CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 20:57:08